Treatment of Advanced Hepatocellular Carcinoma after Failure of Sorafenib Treatment: Subsequent or Additional Treatment Interventions Contribute to Prolonged Survival Postprogression

Table 4

Prognostic factors for survival postprogression based on univariate and multivariate analyses.

Variables		Univariate analysis	Multivariate analysis
		value	value	HR	95% CI
Age	≥75 years	0.851
	<75 years
Sex	Male	0.491
	Female
Cause	HCV	0.572
	Others
Child-Pugh class	A	0.100
	B
BCLC stage	B	0.062
	C
AST (U/L)	<80	0.963
	≥80
ALT (U/L)	<80	0.879
	≥80
Total bilirubin (mg/dL)	<1.0	0.837
	≥1.0
Albumin (g/dL)	<3.6	0.098
	≥3.6
AFP (ng/mL)	≥400	0.022	0.864	1.050	0.603–1.828
	<400
DCP (mAU/mL)	≥400	<0.001	<0.001	3.936	2.066–7.497
	<400
Best overall response	PR+SD	0.317
	PD
Subsequent or additional treatment	Yes	0.037	0.019	0.529	0.310–0.900
	No
Progression of macrovascular invasion	Yes	0.001	0.035	2.025	1.052–3.898
	No
Intrahepatic growth	Yes	0.769
	No
Extrahepatic growth	Yes	0.244
	No
New intrahepatic lesion	Yes	0.081
	No
New extrahepatic lesion	Yes	0.217
	No
Treatment duration before PD (months)	≥3	0.093
	<3
Sorafenib continuation after PD	Yes	0.050
	No

HCV: hepatitis C virus; BCLC: Barcelona clinic liver cancer; AST: aspartate aminotransferase; ALT: alanine aminotransferase; AFP: alpha-fetoprotein; DCP: des-gamma carboxy-prothrombin; PR: partial response; SD: stable disease; PD: progressive disease.